4 completed, 1 terminated. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Terminated 1 |
| Phase 2 | 2 | Completed 2 |
Follow Social Phobia: new trials by email Literature Review of Social Phobia trials Research Report on Social Phobia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Low-Level Laser Stimulation With and Without Fear Extinction Training Extinction Training, Low-Level Laser Therapy, Sham Low-Level Laser Therapy - Phobias, Claustrophobia | Phase 1 / Phase 2 | Completed | University of Texas at Austin | 112 | 2015-08-01 | 2022-12-28 |
| Brief Behavioral Treatment for Anxiety in Young Children Parent-Led Exposure Therapy, Treatment As Usual - Obsessive-compulsive Disorder, Social Phobia | Phase 1 / Phase 2 | Completed | University of South Florida | 58 | 2014-01-01 | 2016-10-06 |
| A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Contraceptive Pills GW876008, COC - Social Phobia | Phase 1 | Terminated | GlaxoSmithKline | 4 | 2007-06-08 | 2017-08-04 |
| A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder GSK561679 tablet, GW876008 tablet, alprazolam - Social Phobia | Phase 1 | Completed | GlaxoSmithKline | 35 | 2007-03-27 | 2017-08-04 |
| A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder Placebo treatment during 8 weeks, Paroxetine treatment during 8 weeks - Social Phobia | Phase 1 | Completed | GlaxoSmithKline | 56 | 2007-01-22 | 2017-07-18 |
Phobia, Social (5) · Anxiety Disorders (2) · Anxiety, Separation (1) · Claustrophobia (1) · Depression (1) · Generalized Anxiety Disorder (1) · Glossophobia (1) · Mutism (1) · Obsessive-Compulsive Disorder (1) · Phobia, Specific (1) · Phobic Disorders (1)
Mental Disorders (5) · Phobic Disorders (4) · Anxiety Disorders (3) · Behavior (1) · Behavioral Symptoms (1) · Communication Disorders (1) · Language Disorders (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurodevelopmental Disorders (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Speech Disorders (1)
GW 876008 (2) · Alprazolam (1) · Implosive Therapy (1) · Low-Level Light Therapy (1) · NBI 77860 (1) · Therapeutics (1)
GlaxoSmithKline (3) · University of South Florida (1) · University of Texas at Austin (1)
Spain (2) · United States (2) · United Kingdom (1)